five
year
us
anthrax
attack
two
year
bioshield
legisl
ratifi
survey
reveal
biodefens
fund
thu
far
produc
hand
product
clinic
develop
w
ith
sign
pandem
allhazard
prepared
act
law
decemb
biomed
advanc
research
develop
author
barda
creat
given
budget
next
two
year
galvan
develop
new
product
counter
secur
threat
includ
biolog
threat
although
hope
push
product
preclin
research
clinic
survey
r
program
biodefens
reveal
small
number
vaccin
therapeut
target
potenti
bioterror
agent
inch
way
clinic
biowarfar
bioterror
use
centuri
terror
weaken
incapacit
defeat
armi
whole
popul
peopl
histor
pathogen
use
natur
occur
plagu
smallpox
howev
new
genet
manipul
technolog
bacteri
viral
cultur
capabl
possibl
engin
organ
resist
common
antibiot
antivir
conduct
bioterror
attack
addit
advanc
modern
travel
trade
diseas
endem
specif
geograph
region
spread
across
globe
exampl
sever
acut
respiratori
syndrom
sar
spread
southeast
asia
throughout
world
within
matter
week
intern
travel
result
worldwid
disrupt
intern
busi
travel
daili
life
wide
report
media
creat
fear
mani
member
public
region
local
diseas
regard
travel
diseas
littl
probabl
spread
develop
countri
advanc
public
health
system
howev
sar
epidem
show
even
citi
advanc
hospit
public
health
system
hong
kong
toronto
could
initi
contain
control
spread
diseas
present
clear
pictur
interest
biodefens
diseas
prevent
treatment
access
commerci
drug
pipelin
databas
govern
public
websit
compani
websit
pharmaceut
news
report
servic
identifi
therapeut
vaccin
develop
sort
inconsist
omiss
determin
stage
develop
product
us
center
diseas
control
prevent
cdc
list
bioterror
agent
box
serv
defin
agent
studi
search
product
develop
categori
categori
b
agent
well
four
categori
c
agent
crimeancongo
hemorrhag
fever
viru
yellow
fever
avian
influenza
subset
influenza
sarsassoci
corona
viru
sarscov
four
select
like
product
develop
biodefens
driven
detail
studi
basi
data
shown
articl
avail
elsewher
us
cdc
list
remain
govern
best
public
estim
current
biolog
threat
provid
direct
research
product
develop
howev
list
activ
document
expect
chang
time
new
threat
emerg
vaccin
therapeut
develop
exist
threat
exampl
compani
develop
vaccin
therapeut
target
exist
pathogen
terrorist
may
genet
modifi
exist
agent
creat
new
agent
seriou
threat
even
effect
vaccin
avail
possibl
bioterror
diseas
agent
may
remain
threat
vaccin
routin
administ
thu
unit
state
resum
univers
administr
smallpox
vaccin
smallpox
would
longer
consid
top
bioterror
threat
exist
smallpox
vaccin
howev
caus
seriou
complic
issu
limit
util
vaccin
drive
develop
safer
smallpox
vaccin
juli
bioshield
legisl
sign
would
provid
billion
ten
year
purchas
vaccin
therapeut
bioterror
agent
although
legisl
creat
guarante
market
design
endstag
acquisit
fund
develop
first
largest
contract
award
bioshield
announc
novemb
worth
million
fiveyear
period
award
vaxgen
brisban
ca
usa
manufactur
deliv
million
dose
anthrax
vaccin
strateg
nation
stockpil
contract
contenti
product
delay
contract
modif
ultim
us
depart
health
human
servic
termin
contract
still
unclear
success
bioshield
promot
develop
biodefens
product
date
larg
pharmaceut
compani
attract
biodefens
market
promis
bioshield
fund
amount
money
involv
great
enough
offset
concern
liabil
limit
market
potenti
although
second
bill
bioshield
ii
introduc
april
still
approv
bioshield
ii
author
includ
tax
incent
spur
capit
invest
intellectu
properti
protect
liabil
limit
half
fund
identifi
develop
vaccin
therapeut
bioterror
agent
target
anthrax
howev
prioriti
govern
spend
biodefens
product
alway
evid
fall
larg
infus
fund
nation
institut
allergi
infecti
diseas
niaid
tularemia
usual
treatabl
antibiot
ceru
concord
ca
usa
univers
new
mexico
albuquerqu
nm
usa
receiv
million
grant
research
develop
tularemia
vaccin
wherea
dynaport
vaccin
compani
dvc
frederick
md
usa
award
fiveyear
million
contract
develop
tularemia
vaccin
nation
biodefens
analysi
countermeasur
center
complet
assess
rank
bioterror
threat
expect
guid
feder
spend
although
assess
deliv
white
hous
januari
seen
small
group
individu
highlevel
secur
clearanc
creation
barda
provid
addit
product
develop
fund
barda
budget
author
facilit
develop
cdc
classifi
agent
could
use
bioterror
three
categori
categori
b
c
detail
see
ref
categori
agent
nine
agent
famili
agent
bioterror
agent
highest
prioriti
biodefens
research
cdc
defin
categori
agent
organ
pose
risk
nation
secur
easili
dissemin
transmit
person
person
result
high
mortal
rate
potenti
major
public
health
impact
might
caus
public
panic
social
disrupt
requir
special
action
public
health
prepared
new
product
counter
secur
threat
includ
biolog
threat
expect
bridg
fund
gap
initi
research
end
product
particularli
challeng
smaller
compani
identifi
prophylact
vaccin
develop
well
six
recent
launch
vaccin
bioterror
threat
tabl
among
vaccin
categori
agent
develop
concentr
anthrax
vaccin
develop
follow
smallpox
plagu
also
signific
activ
categori
vaccin
develop
viral
encephalitid
vaccin
develop
avian
influenza
vaccin
preclin
develop
phase
phase
three
phase
clinic
trial
fig
pipelin
domin
product
earli
stage
develop
vaccin
like
reach
market
next
year
tabl
number
challeng
creat
biodefens
vaccin
includ
provid
protect
multipl
serotyp
mani
pathogen
unstabl
genom
multipl
genotyp
multipl
serotyp
one
exampl
seven
known
serotyp
clostridium
botulinum
neurotoxin
caus
botul
complet
effect
vaccin
must
protect
seven
serotyp
neurotoxin
one
vaccin
botul
phase
trial
effect
two
serotyp
remain
five
vaccin
preclin
develop
one
heptaval
heptaval
vaccin
cost
effect
may
find
accept
outsid
biodefens
market
addit
constraint
recognit
vaccin
creat
strateg
nation
stockpil
must
attribut
stabil
abil
manufactur
larg
scale
highvolum
administr
agent
list
hepat
effect
vaccin
alreadi
exist
fact
identifi
dozen
hepat
vaccin
market
worldwid
three
approv
unit
state
hepat
howev
still
bioterror
concern
vaccin
routin
administ
cdc
estim
new
infect
unit
state
case
report
nation
notifi
diseas
surveil
system
accord
cdc
hepat
vaccin
wide
use
late
number
case
reach
histor
low
although
vaccin
alreadi
approv
sever
bioterror
agent
compani
develop
vaccin
greater
efficaci
improv
safeti
easier
administr
exampl
hadassah
medic
organ
jerusalem
edibl
vaccin
hepat
preclin
develop
one
substanti
chang
sinc
survey
field
ref
decreas
number
vaccin
develop
sar
sarsassoci
coronaviru
ad
categori
c
agent
august
outbreak
infect
peopl
identifi
vaccin
develop
number
drop
ten
activ
develop
sar
product
delay
suspend
mani
compani
diseas
f
e
u
r
e
major
health
concern
sinc
outbreak
berna
biotech
bern
switzerland
vaccin
preclin
develop
announc
abandon
clinic
trial
vaccin
diseas
longer
seen
prioriti
global
health
author
compani
indic
market
epidemiolog
develop
must
evalu
invest
resourc
develop
vaccin
therapeut
sar
howev
sarscov
remain
anim
reservoir
may
reemerg
term
therapeut
product
develop
recent
launch
bioterror
diseas
tabl
among
therapeut
categori
b
agent
develop
concentr
smallpox
therapeut
develop
follow
viral
encephalitid
anthrax
except
therapeut
target
encephalitid
virus
product
develop
categori
b
agent
signific
activ
two
categori
c
agent
howev
therapeut
develop
sar
avian
influenza
respect
therapeut
preclin
develop
clinic
trial
recent
launch
fig
vaccin
therapeut
pipelin
domin
product
preclin
develop
work
therapeut
bioterror
diseas
goal
develop
product
capabl
treat
varieti
infect
outset
mani
diseas
present
flulik
symptom
broadspectrum
therapeut
would
greatest
util
treatment
initi
identif
caus
agent
although
numer
broadspectrum
antibiot
alreadi
avail
test
approv
treatment
specif
bioterror
infect
product
current
use
standardofcar
includ
ciprofloxacin
cipro
bayer
healthcar
wuppert
germani
treatment
anthrax
infect
vaccinia
immun
globulin
treatment
side
effect
smallpox
vaccin
administr
develop
therapeut
viral
diseas
lag
behind
bacteri
diseas
recommend
care
palli
nonspecif
administr
liquid
fever
reduc
eg
ibuprofen
acetaminophen
bed
rest
mani
therapeut
develop
consid
therapeut
vaccin
therapeut
vaccin
often
immunemodul
agentspecif
pharmaceut
given
exposur
protect
recipi
contract
diseas
diminish
sever
diseas
exampl
research
us
armi
medic
research
institut
infecti
diseas
usamriid
fort
detrick
md
usa
develop
two
experiment
therapeut
vaccin
given
exposur
capabl
prevent
ebola
marburg
symptom
lethal
guinea
pig
rhesu
monkey
respect
juvari
biotherapeut
pleasanton
ca
usa
also
develop
codevelop
sever
therapeut
vaccin
potenti
bioterror
agent
anthrax
smallpox
plagu
compani
institut
govern
entiti
program
focus
biodefens
identifi
total
develop
vaccin
develop
therapeut
tabl
group
develop
vaccin
identifi
differ
countri
group
develop
therapeut
identifi
differ
countri
compani
unit
state
domin
list
repres
total
vaccin
develop
total
therapeut
develop
result
partial
due
larg
number
pharmaceut
biotech
compani
unit
state
also
partial
avail
sourc
unit
state
identifi
confirm
compani
involv
biodefens
product
develop
total
three
govern
organ
eight
compani
develop
vaccin
therapeut
broad
rang
compani
repres
includ
vaccinefocus
multin
sanofi
pasteur
lyon
franc
crucel
leiden
netherland
also
compani
focus
biodefens
dvc
frederick
md
usa
small
biotech
firm
vaxin
birmingham
al
usa
sever
govern
agenc
unit
state
especi
niaid
usamriid
involv
agenc
provid
fund
frequent
activ
role
develop
biodefens
vaccin
compani
leverag
proprietari
technolog
develop
multipl
product
specif
diseas
target
acambi
cambridg
uk
develop
vaccin
west
nile
viru
japanes
enceph
viru
dengu
fever
use
proprietari
chimerivax
technolog
base
live
attenu
strain
yellow
fever
viru
basi
exist
yellow
fever
vaccin
gene
encod
antigen
confer
immun
yellow
fever
viru
replac
gene
viru
interest
alphavax
research
triangl
park
nc
usa
develop
vaccin
botulinum
toxin
smallpox
sar
marburg
viru
viral
enceph
use
proprietari
vaccin
vector
system
alphavaccin
platform
system
base
nonpropag
alphaviru
vector
engin
express
select
gene
pathogen
alphavaccin
particl
contain
foreign
antigen
target
lymph
node
infect
dendrit
cell
initi
strong
immun
respons
fund
alphavax
biodefens
vaccin
program
exce
million
come
primarili
us
feder
govern
biotech
compani
avi
biopharma
portland
usa
use
neugen
antisens
technolog
develop
therapeut
varieti
biodefens
diseas
includ
anthrax
dengu
fever
ebola
neugen
antisens
compound
synthet
chemic
backbon
design
provid
stabil
specif
efficaci
function
deliveri
safeti
technolog
expect
enabl
rapid
respons
emerg
threat
decemb
avi
biopharma
sign
twoyear
million
contract
defens
threat
reduct
agenc
fort
belvoir
va
usa
fund
develop
despit
mani
product
current
develop
outlook
biodefens
vaccin
therapeut
bleak
one
product
market
counter
bioterror
agent
late
stage
develop
mani
compani
institut
govern
agenc
work
revers
situat
even
rapidli
chang
landscap
public
health
prioriti
infecti
diseas
necessari
product
attribut
highvolum
administr
make
biodefens
challeng
area
develop
primari
market
driver
develop
vaccin
therapeut
agent
diseas
cdc
list
bioterror
agent
continu
threat
pose
domest
intern
terrorist
avail
govern
fund
bioterror
agent
ongo
threat
develop
world
also
threat
travel
categori
diseas
yellow
fever
dengu
fever
japanes
enceph
typhoid
fever
sever
vaccin
develop
target
travel
design
protect
combin
food
waterborn
agent
develop
broadspectrum
antibiot
antivir
test
approv
use
bioterror
diseas
remain
press
need
diseas
often
diseas
endem
develop
countri
gener
recogn
develop
countri
also
mani
produc
gener
flulik
symptom
outset
may
recogn
bioterror
relat
larg
number
infect
individu
identifi
track
avail
broadspectrum
antibiot
antivir
could
administ
identif
etiolog
agent
would
benefici
gener
medic
commun
mani
broadspectrum
antibiot
alreadi
approv
market
never
test
diseas
cdc
list
potenti
bioterror
agent
efficaci
assur
incent
larg
pharmaceut
compani
test
product
bioterror
diseas
minim
involv
larg
protract
clinic
trial
remot
locat
diseas
without
larg
patient
popul
larger
pharmaceut
compani
may
leeri
liabil
issu
neg
impact
fail
product
compani
stock
ventur
capit
invest
issu
deliveri
stockpil
feder
state
local
govern
also
remain
without
guarante
purchas
larg
agenc
compani
littl
chanc
recov
expenditur
spent
develop
vaccin
therapeut
biodefens
applic
thu
littl
incent
pursu
smaller
pharmaceut
biotech
compani
institut
may
compound
technolog
util
counter
bioterror
agent
may
resourc
complet
product
develop
conduct
clinic
trial
without
addit
support
barda
may
address
concern
earli
determin
whether
effect
